Results 251 to 260 of about 36,119 (263)

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

Lancet Oncology, The, 2018
Noopur S Raje, Evangelos Terpos, Ramón García-Sanz   +2 more
exaly  

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

Journal of Bone and Mineral Research, 2018
Serge Ferrari, Richard Eastell, Michael McClung   +2 more
exaly  

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

Lancet Oncology, The, 2010
David M Thomas,,, Fracp, Keith M Skubitz, J-Y Blay   +2 more
exaly  

Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway

Cell Metabolism, 2015
Adolfo Garcia-Ocaña
exaly  

Denosumab

Reactions Weekly, 2017
openaire   +2 more sources

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

Journal of Clinical Oncology, 2008
Rowan T Chlebowski
exaly  

Denosumab an option for patients with bone metastasis from breast cancer

Ca-A Cancer Journal for Clinicians, 2011
exaly  

Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS

Bone, 2017
Elena Tsourdi, Bente Lomholt Langdahl, Martine Cohen Solal   +2 more
exaly  

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

Nature Reviews Drug Discovery, 2012
exaly  

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

Lancet Diabetes and Endocrinology,the, 2018
Kenneth G Saag, Piet Geusens, Jonathan D Adachi   +2 more
exaly